Molecular diagnostics of non-small cell lung cancer. New markers and technologies

被引：0
|
作者：
Warth, A. [1 ,3 ]
Endris, V. [1 ]
Kriegsmann, M. [1 ]
Stenzinger, A. [1 ]
Penzel, R. [1 ]
Pfarr, N. [1 ]
Weichert, W. [1 ,2 ]
机构：
[1] Univ Klinikum Heidelberg, Inst Pathol, D-69120 Heidelberg, Germany
[2] NCT, Heidelberg, Germany
[3] Mitglied Deutsch Zentrums Lungenforsch DZL TLRC, Translat Lungenforschungszentrum, Heidelberg, Germany
来源：
PATHOLOGE | 2015年 / 36卷 / 02期
关键词：
Lung cancer; Molecular diagnostics; Sequential testing; Massively parallel sequencing; Immunomodulatory drugs; CIRCULATING TUMOR DNA; INTERNATIONAL ASSOCIATION; GENE REARRANGEMENT; MASS-SPECTROMETRY; PLASMA DNA; PHASE-III; ERCC1; ADENOCARCINOMA; CHEMOTHERAPY; CRIZOTINIB;
D O I：
10.1007/s00292-015-0004-4
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Lung cancer is the prototypical tumor entity for the development of new diagnostic and individualized therapeutic strategies based on molecular patient stratification. Developments in this field specifically concentrate on predictive biomarkers for the response to conventional therapeutic agents, novel drugs targeting specific mutations and also new immunomodulatory drugs. The multitude of upcoming new predictive biomarkers requires the development and implementation of efficient test strategies and comprehensive technical methods, specifically when tissue restrictions inherent to lung cancer diagnostics are also taken into account. Novel procedures and technical aspects of these issues are discussed in this review.
引用
收藏
页码：154 / 163
页数：10
相关论文
共 50 条
  • [21] Molecular Diagnostics and Targeted Therapies in Non-small Cell Lung Cancer (NSCLC): An Update
    Jonna, Sushma
    Subramaniam, Deepa S.
    DISCOVERY MEDICINE, 2019, 27 (148) : 167 - 170
  • [22] New generation of cancer stem cells inhibitors in non-small cell lung cancer.
    Labrador, Hector Amado
    Aguilar-Gallardo, Cristobal
    Herreros-Pomares, Alejandro
    Munera-Maravilla, Ester
    Calabuig-Farinas, Silvia
    Escorihuela, Eva
    Murga, Juan
    Jantus-Lewintre, Eloisa
    Camps, Carlos
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Gemcitabine - a new agent in the treatment of non-small cell lung cancer. A commentary
    Carmichael, J
    LUNG CANCER, 1999, 25 (02) : 73 - 75
  • [24] New Molecular Targets on the Horizon in Non-Small Cell Lung Cancer
    Baumgart, Megan
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (06) : 10 - 13
  • [25] Akt and PTEN: New diagnostic markers of non-small cell lung cancer?
    David, O
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2001, 5 (04) : 430 - 433
  • [26] Non-small cell lung cancer. Subtyping and predictive molecular marker investigations in cytology
    Savic, S.
    Bihl, M. P.
    Bubendorf, L.
    PATHOLOGE, 2012, 33 (04): : 301 - 307
  • [27] Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update
    Blons, Helene
    Garinet, Simon
    Laurent-Puig, Pierre
    Oudart, Jean-Baptiste
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S25 - S36
  • [28] A retrospective, descriptive analysis identifying non-small cell lung cancer molecular markers
    Shafiq, Irfan
    Isse, Said
    Khan, Naureen
    Uzebeck, Mateen
    Zoumot, Zaid
    Shabeer, Safia
    Wahla, Ali
    MOLECULAR AND CLINICAL ONCOLOGY, 2024, 20 (06)
  • [29] Advances in the treatment of non-small cell lung cancer: Molecular markers take the stage
    Rosell, R
    Green, M
    Gumerlock, P
    SEMINARS IN ONCOLOGY, 2001, 28 (01) : 28 - 34
  • [30] Trends in ALK inhibitors for non-small cell lung cancer.
    Meade, Denise
    Ng, Marie
    Alford, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345